0.8164

3.18% -0.0268

Pre-market: .84 0.0236 +2.89%

Reviva Pharmaceuticals Holdings Inc (RVPH)

Overview News Price History Option Chain Financials Discussions Forecast

Reviva Pharmaceuticals Holdings Inc stock is traded at $0.8164, with a volume of 613.49K. It is down -3.18% in the last 24 hours and up +13.39% over the past month. Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063), which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis, and its other drug candidate is RP1208.

Previous Close:

$0.8432

Open:

$0.88

24h Volume:

613.49K

Relative Volume:

1.15

Market Cap:

$10.46M

Revenue:

Net Income/Loss:

$-19.86M

P/E Ratio:

-0.1209

EPS:

-6.7506

Net Cash Flow:

$-24.59M

1W Performance:

-7.12%

1M Performance:

+13.39%

6M Performance:

-92.96%

1Y Performance:

-95.21%

1-Day Range:

$0.7544

$0.88

1-Week Range:

$0.7544

$0.9104

52-Week Range:

$0.59

$23.20

Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Company Profile

Name

Reviva Pharmaceuticals Holdings Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

(408) 501-8881

Address

10080 N WOLFE ROAD, CUPERTINO

Employee

Twitter

Next Earnings Date

2026-05-21

Latest SEC Filings

RVPH's Discussions on Twitter

Compare RVPH vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RVPH Reviva Pharmaceuticals Holdings Inc	0.8164	10.46M	0	-19.86M	-24.59M	-6.7506
VRTX Vertex Pharmaceuticals Inc	424.36	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.06B	5.36B	287.73M	924.18M	2.5229

Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-05-26	Downgrade	D. Boral Capital	Buy → Hold
Sep-29-25	Initiated	Chardan Capital Markets	Buy
Sep-20-23	Initiated	ROTH MKM	Buy
Jun-08-23	Initiated	The Benchmark Company	Speculative Buy
Jan-24-22	Initiated	H.C. Wainwright	Buy

Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Latest News

May 05, 2026

Reviva Pharmaceuticals Holdings (RVPH) price target decreased by 50.79% to 38.15 - MSN

May 05, 2026

May 04, 2026

D. Boral Capital downgrades Reviva Pharmaceuticals stock rating to hold - Investing.com

May 04, 2026

Apr 27, 2026

Reviva Pharmaceuticals Holdings (RVPH) price target decreased by 42.03% to 68.00 - MSN

Apr 27, 2026

Apr 26, 2026

Reviva Pharmaceuticals shares tumble after $9M public offering priced - MSN

Apr 26, 2026

Apr 24, 2026

Reviva Pharmaceuticals Holdings (RVPH) price target increased by 14.00% to 77.52 - MSN

Apr 24, 2026

Analysts Offer Insights on Healthcare Companies: Reviva Pharmaceuticals Holdings (RVPH) and Merck & Company (MRK) - The Globe and Mail

Apr 21, 2026

Apr 20, 2026

Maxim Turns Cautious on Reviva Pharmaceuticals Holdings, Inc. (RVPH) Despite Phase 3 Progress Plans - Insider Monkey

Apr 20, 2026

What Analysts Say About Reviva (RVPH) Stock (Steady Decline) 2026-04-20Expert Stock Picks - Xã Thanh Hà

Apr 20, 2026

RVPH: Shareholder Letter Introduces New IP - Yahoo Finance

Apr 20, 2026

5 Oversold Biotech Stocks to Invest In Now - Insider Monkey

Apr 20, 2026

Apr 19, 2026

symbol__ Stock Quote Price and Forecast - CNN

Apr 19, 2026

Apr 17, 2026

Deal Dispatch: Amazon Buys Globalstar, Instacart Grabs Instaleap, QVC Announces BankruptcyAmazon.com - Benzinga

Apr 17, 2026

Apr 16, 2026

Reviva Announces Letter to Shareholders - Sahm

Apr 16, 2026

Apr 15, 2026

Reviva Pharmaceuticals raises $10M, extends cash runway to Q1 2027 - Investing.com Australia

Apr 15, 2026

Reviva Pharmaceuticals Pursues Patent Extension for Brilaroxazine to 2046 and Prepares for Key FDA Milestone in Schizophrenia Program - Minichart

Apr 15, 2026

Reviva Pharmaceuticals outlines patent and development plans for brilaroxazine By Investing.com - Investing.com Australia

Apr 15, 2026

Reviva Updates Brilaroxazine Strategy and Funding Outlook - TipRanks

Apr 15, 2026

Reviva Pharmaceuticals raises $10M, extends cash runway to Q1 2027 By Investing.com - Investing.com South Africa

Apr 15, 2026

Reviva Pharmaceuticals outlines patent and development plans for brilaroxazine - Investing.com

Apr 15, 2026

Reviva Announces patent filing, FDA alignment plans and RECOVER-2 timing - TradingView

Apr 15, 2026

Reviva (NASDAQ: RVPH) maps brilaroxazine IP push and Phase 3 timeline - Stock Titan

Apr 15, 2026

Apr 13, 2026

Aug Weekly: Is Reviva Pharmaceuticals Holdings Inc forming a bullish divergencePortfolio Gains Report & AI Enhanced Trading Alerts - baoquankhu1.vn

Apr 13, 2026

Growth Report: Can Reviva Pharmaceuticals Holdings Inc sustain earnings growthMarket Risk Report & Risk Controlled Stock Pick Alerts - baoquankhu1.vn

Apr 13, 2026

Apr 12, 2026